Nanotein & Akron Bio Partner for cGMP production of NanoSpark® STEM-T Soluble T Cell Activator. Read More
Add NanoSparkTM GROW-NK Soluble Activator to your cart now!
Part Number: GROW-NK
$650.00
If you are purchasing outside of the United States, Canada, China, Germany, Japan, Sweden, Switzerland, Taiwan, or United Kingdom – Please contact info@nanoteintech.com to complete your purchase.
The NanoSparkTM GROW-NK Soluble Activator is a culture-ready, feeder-free reagent for in vitro activation and expansion of human NK cells. The nanoscale of the NanoSparkTM GROW-NK protein complex allows for sterile filtration and removal of excess reagent via either media exchange or simple centrifugal cell washing.
There is no other product like it. It’s simple, easy-to-use, and removes the need for costly, laborious, and risky feeder cells. Competing feeder cells introduce clinical risks to the process by contaminating cell therapies with cancer cells that could also harbor human pathogens.
The NanoSparkTM product line is modular and plug-and-play by design, using a proprietary self-assembly protein nanoparticle complex that is inherently soluble and can be filter sterilized.
The NanoSparkTM GROW-NK Soluble Activator contains self-assembling protein nanoparticles (complexes) with functional antibodies bound to the surface through high-affinity non-covalent interactions. These anti-NKp46 and anti-CD2 antibodies are arranged in a proprietary biophysical combination on the NanoSparkTM platform that drives internal signal transduction or activation.
The NanoSparkTM GROW-NK Soluble Activator activates resting donor human CD3-/CD56+ NK cells.
Need help getting started? Want to benefit most from your NK cell activation and expansion? Contact the Nanotein team today to learn more.
Soluble, feeder-free, protein-based, and ready-to-use.
Industry-leading feeder cell free NK expansion with high viability and cytotoxicity.
Employs anti-NKp46/CD2 antibodies displayed on our versatile NanoSparkTM platform.
| Product Line | NanoSparkTM |
| Cell Type | NK cells |
| Sample Type | PBMC, cell culture, NK cell isolate |
| Reactivity | Human |
| Application | NK cell activators, NK cell manufacturing, immunotherapy |
| Grade | Research grade |
| Quantity | 2 mL |
| Contents | Activator contents suspended in phosphate-buffered saline glycerol |
| Functional Testing | ≥80% expected proliferation of NK cells on day 21 |
| Sterility | Sterile 0.2 µm filtered post-aseptic production |
| Mycoplasma | Negative |
| Storage | Keep frozen at -80°C for long-term storage Once thawed, store at 4°C protected from light for up to one month |
| Shipping Condition | Frozen on dry ice |
| Product Weight | 13.15 g (0.0289 lbs) |
| Product Dimensions | 5 mL clear glass vial (20 mm x 22 mm x 40 mm – vial opening x vial diameter x vial height) |
Consult the data sheets and supporting documentation for usage instructions and additional details, or explore the recommended protocols, which include suggested catalog numbers for cytokine supplements and media.
These protocols are recommended, and include suggested catalog numbers of cytokine supplements and media to use.
NK Data Sheet 2024 (multi-cytokine options)
Lot-specific GROW-NK CoA will be shipped with the product. Contact customer service if additional copies are required.
Carefully read product SDS before use.
Fold Change and Cytotoxicity of NK Cells. NanoSparkTM GROW-NK Soluble Activator was cultured in CellGenix GMP SCGM with and without serum supplemented with the designated cytokines. Cells were expanded, labeled according to the following staining: CD3–, CD16+, CD56+, and NKp46+ using 3 of 3 fluorescent antibodies, and analyzed on a flow cytometer. For the cytotoxicity assay, day 28 expanded effector NK cells were mixed with target K562 cells at 1:1, 5:1, and 10:1 effector to target ratios and incubated for 4 hours. Cells were labeled according to the following staining: CD3–, CD16+, and CD107a+ using fluorescent antibodies. Expansion with NanoSparkTM GROW-NK Soluble Activator enhances total cell viability and stimulates expansion of NK cells while promoting their cytotoxicity.
The underlying NanoSparkTM platform has undergone biocompatibility testing when formulated with antibodies specific to our T cell activator, STEM-T, which we consider a significant derisking step for the platform as a whole. The details are as follows:
The composition of the NanoSparkTM reagent is protein-based, and consequently naturally biodegradable, which provides a significant safety advantage over magnetic bead-based and synthetic products. A reputable medical device CRO was commissioned to complete the in vitro & in vivo ISO 10993 biocompatibility testing. The tests were run at >20X the predicted possible carry-over amount, which resulted in no toxicity or adverse effects:
| ISO 10993 Biocompatibility Testing | Test | Type of Test | Result | Product Tested |
| ISO 10993-5 | Cytotoxicity | In vitro | No Toxicity/Adverse Effect | NanoSpark STEM-T |
| ISO 10993-10 | Sensitization | In vivo: Guinea Pig | No Toxicity/Adverse Effect | NanoSpark STEM-T |
| ISO 10993-10 | Irritation/Intracutaneous Reactivity | In vivo: Rabbits | No Toxicity/Adverse Effect | NanoSpark STEM-T |
| ISO 10993-11 | Acute Systemic Toxicity | In vivo: Mice | No Toxicity/Adverse Effect | NanoSpark STEM-T |
| ISO 10993-11 | Pyrogenicity | In vivo: Rabbits | No Toxicity/Adverse Effect | NanoSpark STEM-T |
| ISO 10993-4 | Hemocompatibility | In vitro | No Toxicity/Adverse Effect | NanoSpark STEM-T |
| ISO 10993-3 | Genotoxicity Ames | In vitro | No Toxicity/Adverse Effect | NanoSpark STEM-T |
| ISO 10993-3 | Genotoxicity Mouse Lymphoma Forward Mutation | In vitro | No Toxicity/Adverse Effect | NanoSpark STEM-T |
The immune system is an intricate nexus of cells and molecules protecting the body against pathogens and diseases. Among the...
Immunotherapy harnesses the power of the human immune system to target and eliminate cancer cells, providing a promising approach in...
The immune system of the human body is a complicated and integrated network of organs, specialized immune cells, and signaling...
Subscribe to Our Newsletter
